BBNX stock forecast, quote, news & analysis
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease... Show more
Why Beta Bionics (BBNX) Stock Is Down -13% in the Last 30 Days
Key Takeaways
- Beta Bionics (BBNX) shares fell roughly 13% over the last 30 days, from about $20.52 on September 28 to near $17.78 in late October.
- The decline accelerated even as the company reported record third-quarter net sales of $35.5 million, up 30% year over year, as widening losses and higher operating expenses weighed on sentiment.
- Over the full quarter the stock remains higher by about 12%, having rallied sharply from late-July levels before pulling back from a late-September peak near $22.81.
- Near-term catalysts include the September FDA clearance of the Mint patch pump, a public offering that raised roughly $161 million, and a partnership with Senseonics (SENS).
- Investor concerns center on securities-fraud class action litigation, a delay on the 3D Intelligence algorithm, and a potential fourth-quarter revenue deferral ahead of the Mint launch.
- With a 52-week range of roughly $8.80 to $32.71, BBNX remains a high-volatility, early-stage growth name.
- For more detail on valuation and expectations, review Beta Bionics' Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how automated strategies are tracking stocks like BBNX.
Beta Bionics (BBNX) Company Overview and Market Position
Beta Bionics is an Irvine, California-based commercial-stage medical device company focused on automated insulin delivery for people with diabetes. Its flagship product, the iLet Bionic Pancreas, uses a proprietary adaptive closed-loop algorithm that autonomously determines every insulin dose — the first FDA-cleared algorithm to do so without requiring users to count carbohydrates. The device received FDA clearance in May 2023 and has since built a growing installed base. The company is broadening its portfolio with Mint, a tubeless patch pump cleared by the FDA in September 2026, and 3D Intelligence, a next-generation dosing algorithm. Investors follow BBNX for its position in the fast-growing automated insulin delivery market, which is also served by companies such as Insulet (PODD), Dexcom (DXCM), and Abbott (ABT).
Beta Bionics (BBNX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, BBNX has declined roughly 13%, from a September 28 close of about $20.52 to around $17.78 in late October. The pullback steepened after the company reported third-quarter results, with shares selling off despite record revenue as investors focused on a wider net loss and rising spending.
The picture looks different over the full quarter. From a late-July close near $15.80, the stock climbed roughly 44% to a late-September peak around $22.81 before reversing. Through late October, it remained up about 12% over the trailing three months — a volatile round trip that reflects both the September product news and the subsequent retracement.
What Drove BBNX Stock Price in the Last 30 Days
Several factors shaped the recent move. First, the company reported record third-quarter net sales of $35.5 million, up 30% year over year, but its net loss widened to $24.4 million, or $0.52 per share, as operating expenses rose 46% to $46.9 million. Gross margin of 57.3% declined 178 basis points sequentially on distributor stocking dynamics. Management raised the lower end of its full-year revenue outlook to $124–126 million, but flagged up to $8.5 million of potential fourth-quarter revenue deferral as prospective iLet users wait for the Mint launch.
Second, litigation risk has risen. Securities-fraud class action lawsuits allege the company misled investors regarding the safety, efficacy, and commercial performance of the iLet device, referencing an FDA Form 483 and a Warning Letter as well as allegedly unreported product complaints. Third, the company disclosed a delay on its 3D Intelligence algorithm after withdrawing a 510(k) submission, pushing iLet 3D and Mint 3D commercialization into the first half of 2027. Together, these headwinds outweighed the positive momentum from the September Mint clearance and a roughly $161 million capital raise.
What Drove BBNX Stock Performance Over the Last Quarter
The broader quarterly trend was dominated by a sharp rally followed by a retracement. Shares surged from late-July levels after the FDA cleared the Mint patch pump in September, the company unveiled its 3D Intelligence algorithm, and it announced a partnership with Senseonics to integrate the Eversense 365 continuous glucose monitor. A public offering that added roughly $161 million in net proceeds strengthened the balance sheet, with cash and investments of about $374 million as of September 30. However, the litigation disclosures and the post-earnings reaction erased much of those gains, leaving the stock modestly higher over the quarter but well off its peak.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies. Tickeron offers hundreds of AI trading bots that collectively trade thousands of tickers, but only the top-performing and most relevant bots appear in this section. These robots vary in strategy, timeframe, and performance metrics, giving traders a range of approaches for monitoring names such as BBNX. The section is designed to help users identify automated signals that match their own objectives and risk tolerance. Exploring the page can offer a data-driven complement to fundamental research for those tracking the stock's next move.
BBNX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to monitor several factors. The full U.S. commercialization of the Mint patch pump in the first quarter of 2027 and the resubmission and clearance of the 3D Intelligence algorithm are central to the company's growth story. Progress on the securities litigation and any related regulatory follow-ups will also matter for sentiment. On fundamentals, watch whether fourth-quarter revenue meets management's $29–31 million guidance, whether the anticipated revenue deferral materializes, and how gross margin and operating expense growth trend. Pharmacy-channel mix and new patient starts remain key indicators of commercial traction. Analysts maintain a consensus "Moderate Buy" rating with an average price target near $23.38, though estimates and targets change frequently. Broader macroeconomic conditions and competition in automated insulin delivery could also influence the stock.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BBNX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for BBNX turned positive on November 11, 2026. Looking at past instances where BBNX's MACD turned positive, the stock continued to rise in 11 of 11 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 13 of 15 cases where BBNX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
Following a +9.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBNX advanced for three days, in 81 of 97 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The 10-day RSI Indicator for BBNX moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 16 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BBNX as a result. In 18 of 25 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
BBNX moved below its 50-day moving average on October 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BBNX crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 3 of 4 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
BBNX broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BBNX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.304) is normal, around the industry mean (4.142). P/E Ratio (-9.812) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (8.251) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. BBNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices